Triple Agonists (GLP-1/GIP/Glucagon) Class Overview Monograph At a glance Prototype agent / retatrutide (LY3437943), Eli Lilly Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor co-agonism Phase 2 peak weight loss / up to 24.2% body weight at 48 weeks (retatrutide 12 mg) Primary indications in development / obesity, type 2 diabetes, MASLD/MASH, dyslipidemia Route and frequency / once-weekly subcutaneous injection Key differentiator from dual agonists / added glucagon receptor activity drives hepatic fat mobilization and energy expenditure Most common adverse effects / nausea, vomiting, diarrhea, constipation (dose-dependent) Regulatory status (as of mid-2025) / phase 3 trials ongoing
Frontiers in Clinical Diabetes and Healthcare 6
following acute MI, prompt L-carnitine administration and subsequent oral maintenance therapy has been shown to attenuate progressive left ventricular dilatation and appears to reduce myocardial injury through improving carbohydrate metabolism and reducing the toxicity of high free fatty acid levels [5, 6]
Improve how your body handles insulin / blood sugar (very helpful in type 2 diabetes)
Liisa AM Galea - Funding acquisition, Project administration, Resources, Supervision, Validation, Writing review & editing
Athletes need hydration after a long workout due to using the energy of the body, muscles, and bones at an accelerated rate
.webp)
